. Author manuscript; available in PMC: 2022 Jun 1.

Published in final edited form as: J Neuroimmune Pharmacol. 2020 Apr 14;16(2):289–305. doi: 10.1007/s11481-020-09914-x

Table 3B.

ALFF and motor performance in the PD group

Regions	F-band	stand.beta	p			stand.beta	p
Parkinson symptoms	R²=.34, F(5,29)=2.94, p=0.029			correlation ^a		age contribution
(UPDRS-III on meds)	R² change=.34, F(3,29)=4.90, p=0.007			r	p

L. SMA, paracentral	LF	.347	0.031	.39	0.027	.060	ns
R. precentral, premotor	LF	.283	0.087	.37	0.034
R. MOG	LF	−.299	0.076	−.35	0.043

	R²=54, F(5,29)=6.93, p<0.0001			correlation ^a		age contribution
(UPDRS-III off meds)	R² change=.47, F(3,29)=10.03, p<0.0001			r	p

Caudate	HF	.305	0.026	.36	0.037	−.230	0.093
R. precentral, premotor	LF	.436	0.003	.49	0.004
L. MOG	LF	.333	0.026	.41	0.018

Ataxia	R²=50, F(5,29)=5.68, p=0.001			correlation ^a		age contribution
(SARA on meds)	R² change=.43, F(3,29)=9.21, p<0.0001			r	p

L. putamen	LF	−.269	0.058	−.35	0.048	−.075	ns
L. dlPFC, dACC	LF	.452	0.006	.37	0.033
L. SMA, paracentral	LF	.526	0.001	.46	0.007

	R²=65, F(8,25)=5.74, p<0.0001			correlation ^a		age contribution
(SARA off meds)	R² change=.60, F(6,25)=7.13, p<0.0001			r	p

Putamen	LF	−.392	0.014	−.48	0.006	−.180	ns
Thalamus	M2	−.423	0.005	−.41	0.020
R. hippocampus	M1	.417	0.019	.35	0.049
L. hippocampus	M1	.049	ns	.35	0.051
L. MOG	LF	.241	ns	.38	0.031
L. dlPFC, dACC	LF	.114	ns	.41	0.019

Hierarchical multiple regression analyses tested the contribution (R² change) of regional ALFF (step 2) while controlling for age and rs-fMRI motion (step 1).

Partial correlation controlling for age and rs-fMRI motion